Kirill Matylitsky

Kirill Matylitsky

Auto-generated profile, based on publicly available information

Kirill Matylitsky

Arbuzov Institute of Organic and Physical Chemistry, FRC Kazan Scientific Center, Russian Academy of Sciences, Akad. Arbuzov St. 8, 420088 Kazan, Russia

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 March 2023 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
Elena ChugunovaElena Chugunova
Elena Chugunova
EGElmira Mingaleevna Gibadullina
Elmira Mingaleevna Gibadullina
KMKirill Matylitsky
Kirill Matylitsky
BBBaurat Bazarbayev
Baurat Bazarbayev
Margarita NeganovaMargarita Neganova
Margarita Neganova
Igor V. AlabuginIgor V. Alabugin
Igor V. Alabugin
Combining two pharmacophores in a molecule can lead to useful synergistic effects. Herein, we show hybrid systems that combine sterically hindered phenols with dinitrobenzofuroxan fragments exhibit a broad range of biological activities. The modular assembly of such phenol/benzofuroxan hybrids allows variations in the phenol/benzofuroxan ratio. Interestingly, the antimicrobial activity only appears when at least two benzofuroxan moieties are introduced per phenol. The most potent of the synthesized compounds exhibit high cytotoxicity against human duodenal adenocarcinoma (HuTu 80), human breast adenocarcinoma (MCF-7), and human cervical carcinoma cell lines. This toxicity is associated with the induction of apoptosis via the internal mitochondrial pathway and an increase in ROS production. Encouragingly, the index of selectivity relative to healthy tissues exceeds that for the reference drugs Doxorubicin and Sorafenib. The biostability of the leading compounds in whole mice blood is sufficiently high for their future quantification in biological matrices.